Positive Results, Close of Public Offerings, Grants, Data Presentations and Partnerships - Research Report on Lexicon, Sangamo Biosciences, Immunomedics, NewLink Genetics, and Pacific Biosciences

News provided by

Oct 04, 2013, 08:00 ET

NEW YORK, October 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), Sangamo Biosciences Inc. (NASDAQ: SGMO), Immunomedics Inc. (NASDAQ: IMMU), NewLink Genetics Corporation (NASDAQ: NLNK), and Pacific Biosciences of California, Inc. (NASDAQ: PACB). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Lexicon Pharmaceuticals, Inc.Research Report

On October 1, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) announced that LX4211, a first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), successfully met the primary endpoint of reducing post-prandial glucose, in a study of patients with type 2 diabetes and moderate to severe renal impairment. "Our hypothesis was that LX4211 would improve glycemic control even in patients with the greatest degree of renal impairment due to its inhibition of SGLT1 in the GI tract," said Pablo Lapuerta, M.D., Lexicon's Chief Medical Officer. "The post-prandial glucose reductions and GLP-1 elevations observed in this study population support the rationale for demonstrating effective HbA1c reduction in a larger, longer-term Phase 3 trial, and provide further support for the clinical differentiation of LX4211 as a first-in-class dual SGLT1 and SGLT2 inhibitor." The Full Research Report on Lexicon Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b63e_LXRX]

Sangamo Biosciences Inc.Research Report

On September 23, 2013, Sangamo BioSciences, inc. (Sangamo BioSciences) announced the closing of its previously announced underwritten public offering of 6.1 million shares of its common stock, as well as 915,000 additional shares pursuant to the full exercise of the over-allotment option given to underwriters. The Company informed that the shares were sold at the public offering price of $10.58 per share (the last closing price of the stock on the date immediately prior to pricing), which brought the aggregate gross proceeds from the offering to approximately $74.2 million, before deducting underwriting discounts and commissions and other offering expenses. The Full Research Report on Sangamo Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/52a6_SGMO]

Immunomedics Inc.Research Report

On September 30, 2013, Immunomedics, Inc. (Immunomedics) announced the beginning of a three-year grant from the Department of Defense (DOD) valued at more than $1.6 million, to evaluate milatuzumab as a treatment of patients with lupus. The Company informed that the clinical trial will be funded by the Peer Reviewed Medical Research Program of the DOD and will enroll around 30 lupus patients at the Cedars Sinai Medical Center in Los Angeles, CA, under the direction of Dr. Daniel J. Wallace, the principal clinical investigator of this project. The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c20d_IMMU]

NewLink Genetics Corporation Research Report

On September 30, 2013, NewLink Genetics Corp. (NewLink Genetics) announced the presentation of data on its lead HyperAcute cancer immunotherapy product candidates at the 2013 European Cancer Congress (ESMO) in Amsterdam, The Netherlands. The data showed greater than expected responses to salvage chemotherapy following treatment with both algenpantucel-L in patients with pancreatic cancer and tergenpumatucel-L in patients with non-small cell lung cancer (NSCLC). "These data indicate that pretreatment with HyperAcute immunotherapy such as algenpantucel-L or tergenpumatucel-L prior to salvage chemotherapy has the potential to increase the sensitivity of cancer cells to chemotherapy that may lead to durable objective and complete responses," commented Nick Vahanian, MD, President and Chief Medical Officer of NewLink Genetics. According to the Company, the clinical benefit of chemo-sensitization is being further investigated in a larger number of patients by assessing objective tumor responses to follow-on chemotherapy after HyperAcute immunotherapy in ongoing clinical trials. The Full Research Report on NewLink Genetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c592_NLNK]

Pacific Biosciences of California, Inc.Research Report

On September 25, 2013, Pacific BioSciences of California, Inc. (Pacific Biosciences) announced that it has entered into an agreement with Roche Diagnostics for developing diagnostic products, based on the Company's Single Molecule, Real-Time (SMRT^®) technology. Pacific Biosciences will develop and manufacture certain products intended for clinical use, which it will sell exclusively to Roche. Mike Hunkapiller, President and CEO of Pacific Biosciences said, "As a world leader in in vitro diagnostics, Roche brings valuable expertise in designing products for clinical use and obtaining regulatory approvals to sell clinical products in the U.S. and around the world. We believe the combination of our SMRT Sequencing technology with Roche's market position and expertise in diagnostics will allow accelerated commercial success for both companies." The Full Research Report on Pacific Biosciences of California, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/caf8_PACB]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner